This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 19-22, 2025
Manchester Grand Hyatt San DiegoSan Diego, CA

Bruce Morimoto, PhD
Drug Development Advisor at Alto Neuroscience
Speaker

Profile

Dr Morimoto has nearly 30 years of industry experience in leading project teams in the development of innovative medicines, providing guidance in the design and execution of nonclinical, clinical and regulatory strategies with a therapeutic focus on CNS indications including Parkinson’s, Alzheimer’s, ALS and frontotemporal dementias. Previously, Bruce held leadership roles at Alto Neuroscience, Cerecin, Alkahest, Celerion and Allon Therapeutics, and works closely as a scientific advisor to the Michael J Fox Foundation, chairing one of their scientific review panels. He is currently an advisor to several biotech companies helping to move their programs through clinical development and drug registration.


Bruce started his career on the faculty in the Chemistry Department at Purdue University where his independent research focused on neuronal signal transduction. Bruce earned his doctorate in biochemistry from UCLA and completed a postdoctoral fellowship at the University of California Berkeley.

Agenda Sessions

  • The Importance of CMC and Safety Studies in the Design and Execution of First in Human Studies

    11:45am